Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma

Figure 11  Comparison of immune checkpoints, tumor immune dysfunction, and exclusion module scores, and chemotherapy and targeted therapy drug efficacy in high- and low-risk groups. A: Expression of 28 immune checkpoint genes differed between the high- and low-risk groups. Red and blue boxes represent high- and low-risk patients, respectively; B: Online software tumor immune dysfunction (TIDE) predictions of outcomes in HCC subgroups treated with either anti-PD1 or anti-CTLA4 therapy. A higher TIDE score suggests a greater likelihood of tumor immune escape and a poorer response to immunotherapy; C-J: IC₅₀ values for (C) 5-fluorouracil, (D) gemcitabine, (E) paclitaxel, (F) imatinib, (G) sunitinib, (H) rapamycin, (I) XL-184 (cabozantinib), and (J) erlotinib in high- and low-risk groups. IC₅₀, half-maximal inhibitory concentration. ^aP < 0.05; ^bP < 0.01; ^cP < 0.001. NS: Not significant.